

# Medicapital, Inc

Date: June 22, 2009

To: CEO

From: Stephanie Ramirez

Subject: Medicapital, Inc looking to invest in a company on the cutting edge of medicine.

After researching five of the companies requested interesting information was learned about each one individually. The information that was taken mostly into consideration was how long each company had been in business, if the clinical trial involved drugs, the stocks 52 week high and low prices, and if they had any partnership with other companies already in place.

In the Crucell NV very interesting facts were found, making this company one of the top companies that will be recommended to invest in. Another recommended company would be Mannkind Corporation. Both these companies are doing their best to improve the lives of people with cancer and other infectious diseases.

Other companies researched was the Applera Corp-Celera, Crucell NV, and Mannkind Corp. In the Applera Corp-Celera the company was separated and Celera is now a independent, publicly traded company. Celera uses information of human unpredictability to offer new tests to personalize disease management. Abbott serves as their distribution partner, which they develop a variety of molecular diagnostic products. Celera was founded May 1998. For Celera the 52-week high/low was \$17.65/ \$5.03.

The Crucell NV Company is an incorporated biopharmaceutical company. Their focus is to come up with products that fight infectious diseases. Crucell first started in 1993 as a small company. Crucell sold millions of vaccines to about 80 countries. Crucell also has many partners such as DSM biologics, Novartis, Sonofi Aventus, and others. The 52-week high/low was \$24.08/\$9.42.

Mannkind Corporation has clinical trials; it currently has started a phase 1 clinical study for an investigational cancer immunotherapy. MKC1106-PP is the first cancer immunotherapy by this company. This trial is made to target two tumor specific antigens. This company is also conducting another clinical trial of ultra rapid acting insulin that is inhaled through a small device; MKC1106. This company's 52-week high/low was \$9.25/\$2.

The Onxy Pharmaceuticals Company is a biopharmaceutical company that looks forward to helping people with cancer by changing the way this illness is treated. This company was established in 1992, the company has been in business 17 years. Nexavar is their main product that focuses on protein involved in tumor cell proliferation and angiogenesis. Nexavar is also being evaluated in trials for lung cancer and other types of cancer. It is also being revised in several phase 2 trials and also in some phase 1 trials. Onyx and Bayer Pharmaceuticals supports many of these trials. The 52-week high/low was \$45.69/\$21.66.

United Therapeutics Corporation is another company that was researched. This is a company that is centered on the making of good products that to help those patients that need appropriate medical care. These are patients that are dealing with cancer and cardiovascular disease. United

Therapeutics task is taken out by using corporate partners for sales and research. They are currently coming up with treatments to help neuroblastoma and metastatic brain cancer. The 52-week high/low was \$117.82/\$47.63.

The Crucell NV Company and the Mannkind Corporation are both great companies. They both had partnership with other companies. They also have both been in business for many years. After researching the five different companies, these two had great things to offer and are recommended to look into for further investment. Medicapitol should really look into working with Crucell NV and the Mannkind Corporation.